Picard Medical Highlights Artificial Heart Technology on FOX Business

Event summary

  • Picard Medical, parent company of SynCardia, will feature its Total Artificial Heart (STAH) on FOX Business News’ BTV program on March 14, 2026.
  • The STAH has been used in over 2,100 implants globally and is approved by both the U.S. FDA and Health Canada.
  • SynCardia is developing a next-generation, fully implantable artificial heart platform to improve patient mobility.
  • BTV is a long-running investment-focused program reaching retail and institutional investors.

The big picture

Picard Medical’s reliance on the STAH, while currently dominant with over 2,100 implants, exposes the company to technological disruption and increasing competition in the mechanical circulatory support market. The BTV segment serves as a marketing push while the company develops its next-generation platform, highlighting the need to maintain market share and demonstrate continued innovation. The company’s financial performance is heavily tied to reimbursement rates and the overall growth of the heart failure patient population.

What we're watching

Market Adoption
The visibility gained from the BTV segment could accelerate adoption of the STAH, but success hinges on demonstrating clinical efficacy and cost-effectiveness relative to emerging alternatives.
Next-Gen Development
The progress of the fully implantable artificial heart platform will be critical; delays or setbacks could impact Picard Medical’s long-term competitive position.
Regulatory Landscape
Continued regulatory approvals in key international markets will be essential for expanding the STAH’s global reach and offsetting potential pricing pressures in the US and Canada.

Related topics

Medical Devices